1887

Chapter 41 : Filoviruses

Author: Mike Bray
Content Type: Reference
Publication Year: 2009

Category: Viruses and Viral Pathogenesis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Filoviruses, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap41-1.gif /docserver/preview/fulltext/10.1128/9781555815981/9781555814250_Chap41-2.gif

Abstract:

The two genera of filoviruses, and , are certainly the most virulent, and are possibly the most mysterious, of the viral pathogens that afflict humans. Person-to-person transmission occurs almost exclusively through direct contact with virus-containing body fluids, and there is no evidence of spread by insect vectors or the respiratory route. The major filoviral matrix protein, VP40, the most abundant protein in the virion, is the driving force behind the assembly and release of new viral particles from infected cells. Both Marburg and Ebola viruses have been recovered from wild African primates, but it is clear that those animals cannot serve as maintenance hosts, because their populations are too small to support the spread of a rapidly lethal disease. Instead, it appears likely that the filoviruses persist through continuous transmission in one or more species of small animals that are widely distributed in central Africa. Filoviruses replicate to high titers in many types of cultured cells, including Vero monkey kidney cells, human umbilical vein endothelial cells, and primary human macrophages. Cultured human macrophages infected with Ebola Zaire virus release the proinflammatory cytokines and chemokines tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), macrophage inflammatory protein 1α (MIP-1α), MIP-1β, alpha interferon (IFN-1α), and RANTES into the growth medium. Reverse transcription-PCR (RT-PCR) has been found to be more sensitive than antigen-based tests for rapid diagnosis; in the Gulu epidemic, the technique identified infected patients 24 to 48 h earlier than an enzyme-linked immunosorbent assay (ELISA) method.

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Filoviruses
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch41-1,webId=/content/author/10.1128/9781555815981.ch41-1,properties={foaf_givenname=Mike, foaf_name=Mike Bray, foaf_surname=Bray}]]
Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
/content/10.1128/9781555815981.ch41.ch41fig01
FIGURE 1
Members of an outbreak response team collect a saliva sample for testing by RT-PCR during the epidemic of Marburg hemorrhagic fever in Uige, Angola, in 2005. Saliva testing can accurately identify patients with full-blown filoviral hemorrhagic fever, but it is less sensitive than blood testing for detecting cases early in the disease course. (Courtesy of Steve Jones, Arthur Marx, and Ute Stroher, Public Health Agency of Canada.)
10.1128/9781555815981/f0924-01_thmb.gif
10.1128/9781555815981/f0924-01.gif
Image of FIGURE 1
FIGURE 1

Members of an outbreak response team collect a saliva sample for testing by RT-PCR during the epidemic of Marburg hemorrhagic fever in Uige, Angola, in 2005. Saliva testing can accurately identify patients with full-blown filoviral hemorrhagic fever, but it is less sensitive than blood testing for detecting cases early in the disease course. (Courtesy of Steve Jones, Arthur Marx, and Ute Stroher, Public Health Agency of Canada.)

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch41.ch41fig02
FIGURE 2
(A) Negative-contrast electron micrograph of Ebola Zaire virus virions, concentrated by centrifugation from a Vero cell supernatant and dried onto a grid (magnification, ×17,000); (B) transmission electron micrograph of nucleocapsids in a cytoplasmic inclusion body in an infected hepatocyte; (C) scanning electron micrograph of Ebola Zaire virus virions budding from the surface of an infected primary human umbilical vein endothelial cell. (Courtesy of Tom Geisbert, USAMRIID.)
10.1128/9781555815981/f0925-01_thmb.gif
10.1128/9781555815981/f0925-01.gif
Image of FIGURE 2
FIGURE 2

(A) Negative-contrast electron micrograph of Ebola Zaire virus virions, concentrated by centrifugation from a Vero cell supernatant and dried onto a grid (magnification, ×17,000); (B) transmission electron micrograph of nucleocapsids in a cytoplasmic inclusion body in an infected hepatocyte; (C) scanning electron micrograph of Ebola Zaire virus virions budding from the surface of an infected primary human umbilical vein endothelial cell. (Courtesy of Tom Geisbert, USAMRIID.)

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch41.ch41fig03
FIGURE 3
(A) Diagram of a filovirus virion, showing the single-stranded negative-sense RNA genome with its associated nucleocapsid proteins, enveloped in a lipid bilayer bearing GP spikes. The NP and VP30 bind to virion RNA to make up the nucleocapsid, and VP35 and the polymerase (L protein) join them in forming a replication complex. Matrix proteins VP24 and VP40 link the nucleocapsid to GP embedded in the lipid membrane bilayer. (B) Schematic representation of the genomes of Marburg and Ebola viruses. The seven genes encoding viral structural proteins are drawn roughly to scale; coding regions are shaded. Most genes are separated by intergenic regions (IR), but some overlap in short sequences containing a conserved transcriptional signal. Indicated for Ebola virus is the “editing site” at which transcription of the GP gene generates either a full-length membrane-anchored GP or a nonstructural sGP, depending upon whether the polymerase does or does not add a single uncoded adenosine.
10.1128/9781555815981/f0925-02_thmb.gif
10.1128/9781555815981/f0925-02.gif
Image of FIGURE 3
FIGURE 3

(A) Diagram of a filovirus virion, showing the single-stranded negative-sense RNA genome with its associated nucleocapsid proteins, enveloped in a lipid bilayer bearing GP spikes. The NP and VP30 bind to virion RNA to make up the nucleocapsid, and VP35 and the polymerase (L protein) join them in forming a replication complex. Matrix proteins VP24 and VP40 link the nucleocapsid to GP embedded in the lipid membrane bilayer. (B) Schematic representation of the genomes of Marburg and Ebola viruses. The seven genes encoding viral structural proteins are drawn roughly to scale; coding regions are shaded. Most genes are separated by intergenic regions (IR), but some overlap in short sequences containing a conserved transcriptional signal. Indicated for Ebola virus is the “editing site” at which transcription of the GP gene generates either a full-length membrane-anchored GP or a nonstructural sGP, depending upon whether the polymerase does or does not add a single uncoded adenosine.

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch41.ch41fig04
FIGURE 4
(A) In situ hybridization of viral RNA in marginal-zone macrophages of the spleen of a mouse, day 3 after infection with mouse-adapted Ebola Zaire virus. (Courtesy of Tammy Gibb, USAMRIID.) (B) Multifocal necrosis in the liver of a mouse 4 days after infection with the same virus. Some infected hepatocytes contain large acidophilic viral inclusions (arrowhead). (Courtesy of Kelly Davis, USAMRIID.)
10.1128/9781555815981/f0927-01_thmb.gif
10.1128/9781555815981/f0927-01.gif
Image of FIGURE 4
FIGURE 4

(A) In situ hybridization of viral RNA in marginal-zone macrophages of the spleen of a mouse, day 3 after infection with mouse-adapted Ebola Zaire virus. (Courtesy of Tammy Gibb, USAMRIID.) (B) Multifocal necrosis in the liver of a mouse 4 days after infection with the same virus. Some infected hepatocytes contain large acidophilic viral inclusions (arrowhead). (Courtesy of Kelly Davis, USAMRIID.)

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch41.ch41fig05
FIGURE 5
Immunoperoxidase-stained skin biopsy sample from a fatal case of Ebola Zaire virus infection in the 1995 Kikwit outbreak. Viral antigen is seen in fibroblasts and endothelial cells, outlining small vessels (arrowhead). (Courtesy of Sherif Zaki, CDC.)
10.1128/9781555815981/f0930-01_thmb.gif
10.1128/9781555815981/f0930-01.gif
Image of FIGURE 5
FIGURE 5

Immunoperoxidase-stained skin biopsy sample from a fatal case of Ebola Zaire virus infection in the 1995 Kikwit outbreak. Viral antigen is seen in fibroblasts and endothelial cells, outlining small vessels (arrowhead). (Courtesy of Sherif Zaki, CDC.)

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch41.ch41fig06
FIGURE 6
Pathogenetic mechanisms of filoviral hemorrhagic fever, based on data from human cases and studies of lethal infection of rodents and nonhuman primates. Macrophages are the primary site of viral replication. Suppression of type I interferon responses permits rapid dissemination from the initial site of infection to macrophages and dendritic cells in the spleen, lymph nodes, and other lymphoid tissues and to hepatocytes and parenchymal cells of other organs, resulting in extensive necrosis. At the same time, the release of proinflammatory cytokines, chemokines, nitric oxide, and other mediators and the production of cell surface tissue factor by infected macrophages cause a diffuse increase in vascular permeability and DIC, producing a systemic inflammatory syndrome resembling septic shock. Lymphocytes remain uninfected but undergo programmed cell death, apparently brought about through the proapoptoptic effects of inflammatory mediators and a loss of normal support signals from infected dendritic cells. The massive loss of lymphocytes and dendritic cells creates a state of “immune paralysis” in the terminal phase of illness.
10.1128/9781555815981/f0932-01_thmb.gif
10.1128/9781555815981/f0932-01.gif
Image of FIGURE 6
FIGURE 6

Pathogenetic mechanisms of filoviral hemorrhagic fever, based on data from human cases and studies of lethal infection of rodents and nonhuman primates. Macrophages are the primary site of viral replication. Suppression of type I interferon responses permits rapid dissemination from the initial site of infection to macrophages and dendritic cells in the spleen, lymph nodes, and other lymphoid tissues and to hepatocytes and parenchymal cells of other organs, resulting in extensive necrosis. At the same time, the release of proinflammatory cytokines, chemokines, nitric oxide, and other mediators and the production of cell surface tissue factor by infected macrophages cause a diffuse increase in vascular permeability and DIC, producing a systemic inflammatory syndrome resembling septic shock. Lymphocytes remain uninfected but undergo programmed cell death, apparently brought about through the proapoptoptic effects of inflammatory mediators and a loss of normal support signals from infected dendritic cells. The massive loss of lymphocytes and dendritic cells creates a state of “immune paralysis” in the terminal phase of illness.

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/10.1128/9781555815981.ch41.ch41fig07
FIGURE 7
Extensive desquamation of the forearm and hand of an Ebola Sudan virus survivor, 3 weeks after disease onset, Gulu, Uganda, 2000. (Courtesy of Dan Bausch, Tulane University.)
10.1128/9781555815981/f0933-01_thmb.gif
10.1128/9781555815981/f0933-01.gif
Image of FIGURE 7
FIGURE 7

Extensive desquamation of the forearm and hand of an Ebola Sudan virus survivor, 3 weeks after disease onset, Gulu, Uganda, 2000. (Courtesy of Dan Bausch, Tulane University.)

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815981.ch41
1. Akinfeeva, A.,, O. Aksionova,, I. Vasilevich,, A. Gin’ko,, K. Zar’kov,, N. Zybavichene,, L. Katkova,, O. Kuzovlev,, V. Kuzubov,, L. Lokteva, and, E. Ryabchikova. 2005. A case of Ebola hemorrhagic fever. Infektsionnie Bolezni 3: 85– 88.
2. Aman, M. J.,, C. M. Bosio,, R. G. Panchal,, J. C. Burnett,, A. Schmaljohn, and, S. Bavari. 2003. Molecular mechanisms of filovirus cellular trafficking. Microbes Infect. 5: 639– 649.
3. Basler, C. F.,, A. Mikulasova,, L. Martinez-Sobrido,, J. Paragas,, E. Muhlberger,, M. Bray,, H. D. Klenk,, P. Palese, and, A. Garcia-Sastre. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77: 7945– 7956.
4. Bausch, D.,, H. Feldmann,, T. Geisbert,, M. Bray,, A. Sprecher,, P. Boumandouki,, P. Rollin, and, C. Roth. 2007. Filovirus outbreaks: time to refocus on the patient. J. Infect. Dis. 196 (Suppl. 2) : S136– S141.
5. Bausch, D. G.,, M. Borchert,, T. Grein,, C. Roth,, R. Swanepoel,, M. L. Libande,, A. Talarmin,, E. Bertherat,, J. J. Muyembe-Tamfum,, B. Tugume,, R. Colebunders,, K. M. Konde,, P. Pirad,, L. L. Olinda,, G. R. Rodier,, P. Campbell,, O. Tomori,, T. G. Ksiazek, and, P. E. Rollin. 2003. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg. Infect. Dis. 9: 1531– 1537.
6. Bausch, D. G.,, S. T. Nichol,, J. J. Muyembe-Tamfum,, M. Borchert,, P. E. Rollin,, H. Sleurs,, P. Campbell,, F. K. Tshioko,, C. Roth,, R. Colebunders,, P. Pirard,, S. Mardel,, L. A. Olinda,, H. Zeller,, A. Tshomba,, A. Kulidri,, M. L. Libande,, S. Mulangu,, P. Formenty,, T. Grein,, H. Leirs,, L. Braack,, T. Ksiazek,, S. Zaki,, M. D. Bowen,, S. B. Smit,, P. A. Leman,, F. J. Burt,, A. Kemp, and, R. Swanepoel. 2006. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 355: 909– 919.
7. Bavari, S.,, C. M. Bosio,, E. Wiegand,, G. Ruthel,, A. B. Will,, T. W. Geisbert,, M. Hevey,, C. Schmaljohn,, A. Schmaljohn, and, M. J. Aman. 2002. Lipid raft micro-domains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195: 593– 602.
8. Becker, S.,, H. Feldmann,, C. Will, and, W. Slenczka. 1992. Evidence for occurrence of filovirus antibodies in humans and imported monkeys: do subclinical filovirus infections occur worldwide? Med. Microbiol. Immunol. 181: 43– 55.
9. Bockeler, M.,, U. Stroher,, J. Seebach,, T. Afanasieva,, N. Suttorp,, H. Feldmann, and, H. J. Schnittler. 2007. Breakdown of para-endothelial barrier function in Marburg virus infection is associated with early tyrosine phosphorylation of PECAM-1. J. Infect. Dis. 196 (Suppl. 2) : S337– S346.
10. Bradfute, S.,, D. Braun,, J. Shamblin,, J. Geisbert,, J. Paragas,, L. Hensley, and, T. Geisbert. 2007. Lymphocyte death in a mouse model of Ebola virus infection. J. Infect. Dis. 196 (Suppl. 2) : S296– S304.
11. Bray, M. 2005. Pathogenesis of viral hemorrhagic fever. Curr. Opin. Immunol. 17: 399– 403.
12. Bray, M.,, K. Davis,, T. Geisbert,, C. Schmaljohn, and, J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178: 651– 661.
13. Bray, M.,, S. Hatfill,, L. Hensley, and, J. W. Huggins. 2001. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 125: 243– 253.
14. Bray, M.,, and S. Mahanty. 2003. Ebola hemorrhagic fever and septic shock. J. Infect. Dis. 188: 1613– 1617.
15. Bray, M.,, and J. Paragas. 2002. Experimental therapy of filovirus infections. Antiviral Res. 54: 1– 17.
16. Bukreyev, A.,, P. E. Rollin,, M. K. Tate,, L. Yang,, S. R. Zaki,, W. J. Shieh,, B. R. Murphy,, P. L. Collins, and, A. Sanchez. 2007. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81: 6379– 6388.
17. Busico, K. M.,, K. L. Marshall,, T. G. Ksiazek,, T. H. Roels,, Y. Fleerackers,, H. Feldmann,, A. S. Khan, and, C. J. Peters. 1999. Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1) : S102– S107.
18. Bwaka, M. A.,, M. J. Bonnet,, P. Calain,, R. Colebunders,, A. De Roo,, Y. Guimard,, K. R. Katwiki,, K. Kibadi,, M. A. Kipasa,, K. J. Kuvula,, B. B. Mapanda,, M. Massamba,, K. D. Mupapa,, J. J. Muyembe-Tamfum,, E. Ndaberey,, C. J. Peters,, P. E. Rollin, and, E. Van den Enden. 1999. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 179 (Suppl. 1) : S1– S7.
19. Centers for Disease Control. 1990. Update: filovirus infection among persons with occupational exposure to nonhuman primates. Morb. Mortal. Wkly. Rep. 39: 266.
20. Daddario-DiCaprio, K. M.,, T. W. Geisbert,, U. Stroher,, J. B. Geisbert,, A. Grolla,, E. A. Fritz,, L. Fernando,, E. Kagan,, P. B. Jahrling,, L. E. Hensley,, S. M. Jones, and, H. Feldmann. 2006. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in nonhuman primates: an efficacy assessment. Lancet 367: 1399– 1404.
21. Dowell, S. F.,, R. Mukunu,, T. G. Ksiazek,, A. S. Khan,, P. E. Rollin, and, C. J. Peters for the Commission de Lutte contre les Epidémies à Kikwit. 1999. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1) : S87– S91.
22. Ebihara, H.,, A. Takada,, D. Kobasa,, S. Jones,, G. Neumann,, S. Theriault,, M. Bray,, H. Feldmann, and, Y. Kawaoka. 2006. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2: e73.
23. Emond, R. T.,, B. Evans,, E. T. Bowen, and, G. Lloyd. 1977. A case of Ebola virus infection. Br. Med. J. 2: 541– 544.
24. Feldmann, H.,, H. Bugany,, F. Mahner,, H. D. Klenk,, D. Drenckhahn, and, H. J. Schnittler. 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70: 2208– 2214.
25. Feldmann, H.,, S. M. Jones,, K. M. Daddario-Dicaprio,, J. B. Geisbert,, U. Stroher,, A. Grolla,, M. Bray,, E. A. Fritz,, L. Fernando,, F. Feldmann,, L. E. Hensley, and, T. W. Geisbert. 2007. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 3: e2.
26. Feldmann, H.,, V. E. Volchkov,, V. A. Volchkova, and, H. D. Klenk. 1999. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch. Virol. Suppl. 15: 159– 169.
27. Formenty, P.,, C. Hatz,, B. Le Guenno,, A. Stoll,, P. Rogenmoser, and, A. Widmer. 1999. Human infection due to Ebola virus, subtype Cote d’Ivoire: clinical and biologic presentation. J. Infect. Dis. 179 (Suppl. 1) : S48– S53.
28. Gear, J. S.,, G. A. Cassel,, A. J. Gear,, B. Trappler,, L. Clausen,, A. M. Meyers,, M. C. Kew,, T. H. Bothwell,, R. Sher,, G. B. Miller,, J. Schneider,, H. J. Koornhof,, E. D. Gomperts,, M. Isaacson, and, J. H. Gear. 1975. Outbreak of Marburg virus disease in Johannesburg. Br. Med. J. 4: 489– 493.
29. Geisbert, T.,, K. Daddario-DiCaprio,, J. Geisbert,, E. Fritz,, H. Young,, P. Formenty,, T. Larsen, and, L. Hensley. 2007. Marburg (Angola) virus infection of rhesus monkeys: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 196 (Suppl. 2) : S372– S381.
30. Geisbert, T. W.,, L. E. Hensley,, T. R. Gibb,, K. E. Steele,, N. K. Jaax, and, P. B. Jahrling. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Investig. 80: 171– 186.
31. Geisbert, T. W.,, L. E. Hensley,, P. B. Jahrling,, T. Larsen,, J. B. Geisbert,, J. Paragas,, H. A. Young,, T. M. Fredeking,, W. E. Rote, and, G. P. Vlasuk. 2003. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362: 1953– 1958.
32. Geisbert, T. W.,, L. E. Hensley,, E. Kagan,, E. Z. Yu,, J. B. Geisbert,, K. Daddario-Dicaprio,, E. A. Fritz,, P. B. Jahrling,, K. McClintock,, J. R. Phelps,, A. C. Lee,, A. Judge,, L. B. Jeffs, and, I. Maclachlan. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193: 1650– 1657.
33. Geisbert, T. W.,, H. A. Young,, P. B. Jahrling,, K. J. Davis,, E. Kagan, and, L. E. Hensley. 2003. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188: 1618– 1629.
34. Geisbert, T. W.,, H. A. Young,, P. B. Jahrling,, K. J. Davis,, T. Larsen,, E. Kagan, and, L. E. Hensley. 2003. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virusinduced cytolysis of endothelial cells. Am. J. Pathol. 163: 2371– 2382.
35. Georges-Courbot, M. C.,, C. Y. Lu,, J. Lansoud-Soukate,, E. Leroy, and, S. Baize. 1997. Isolation and partial molecular characterisation of a strain of Ebola virus during a recent epidemic of viral haemorrhagic fever in Gabon. Lancet 349: 181.
36. Gibb, T. R.,, M. Bray,, T. W. Geisbert,, K. E. Steele,, W. M. Kell,, K. J. Davis, and, N. K. Jaax. 2001. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125: 233– 242.
37. Gupta, M.,, S. Mahanty,, M. Bray,, R. Ahmed, and, P. E. Rollin. 2001. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75: 4649– 4654.
38. Hartlieb, B.,, and W. Weissenhorn. 2006. Filovirus assembly and budding. Virology 344: 64– 70.
39. Hensley, L.,, E. Stevens,, S. Yan,, J. Geisbert,, W. Macias,, T. Larsen,, K. Daddario-DiCaprio,, G. Cassell,, P. Jahrling, and, T. Geisbert. 2007. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196 (Suppl. 2) : S390– S399.
40. Hensley, L. E.,, H. A. Young,, P. B. Jahrling, and, T. W. Geisbert. 2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80: 169– 179.
41. Hutchinson, K.,, and P. Rollin. 2007. Cytokine and chemokine expression in humans infected with Ebola Sudan virus. J. Infect. Dis. 196 (Suppl. 2) : S357– S363.
42. Jahrling, P.,, J. Geisbert,, J. Swearengen,, T. Larsen, and, T. Geisbert. 2007. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196 (Suppl. 2) : S400– S403.
43. Jahrling, P. B.,, T. W. Geisbert,, D. W. Dalgard,, E. D. Johnson,, T. G. Ksiazek,, W. C. Hall, and, C. J. Peters. 1990. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335: 502– 505.
44. Jahrling, P. B.,, T. W. Geisbert,, J. B. Geisbert,, J. R. Swearengen,, M. Bray,, N. K. Jaax,, J. W. Huggins,, J. W. LeDuc, and, C. J. Peters. 1999. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179 (Suppl. 1) : S224– S234.
45. Jasenosky, L. D.,, and Y. Kawaoka. 2004. Filovirus budding. Virus Res. 106: 181– 188.
46. Jeffs, B. 2006. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop. Dr. 36: 1– 4.
47. Jeffs, B.,, M. Iscla,, I. Grovas,, C. Dorion,, M. H. Bengi,, P. N. Folo,, P. Roddy,, O. de la Rosa,, D. Weatherill,, P. P. Palma,, O. Bernal,, J. Rodriguez-Martinez,, B. Barcelo,, D. Pou, and, M. Borchert. 2007. The MSF intervention in the Uige Marburg Epidemic 2005—lessons learnt in Uige Provincial Hospital. J. Infect. Dis. 196 (Suppl. 2) : S154– S161.
48. Jones, S. M.,, H. Feldmann,, U. Stroher,, J. B. Geisbert,, L. Fernando,, A. Grolla,, H. D. Klenk,, N. J. Sullivan,, V. E. Volchkov,, E. A. Fritz,, K. M. Daddario,, L. E. Hensley,, P. B. Jahrling, and, T. W. Geisbert. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11: 786– 790.
49. Khan, A. S.,, F. K. Tshioko,, D. L. Heymann,, B. Le Guenno,, P. Nabeth,, B. Kerstiens,, Y. Fleerackers,, P. H. Kilmarx,, G. R. Rodier,, O. Nkuku,, P. E. Rollin,, A. Sanchez,, S. R. Zaki,, R. Swanepoel,, O. Tomori,, S. T. Nichol,, C. J. Peters,, J. J. Muyembe-Tamfum, and, T. G. Ksiazek for the Commission de Lutte contre les Epidémies à Kikwit. 1999. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1) : S76– S86.
50. Ksiazek, T. G.,, P. E. Rollin,, A. J. Williams,, D. S. Bressler,, M. L. Martin,, R. Swanepoel,, F. J. Burt,, P. A. Leman,, A. S. Khan,, A. K. Rowe,, R. Mukunu,, A. Sanchez, and, C. J. Peters. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1) : S177– S187.
51. Ksiazek, T. G.,, C. P. West,, P. E. Rollin,, P. B. Jahrling, and, C. J. Peters. 1999. ELISA for the detection of antibodies to Ebola viruses. J. Infect. Dis. 179 (Suppl. 1) : S192– S198.
52. Kudoyarova-Zubavichene, N. M.,, N. N. Sergeyev,, A. A. Chepurnov, and, S. V. Netesov. 1999. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J. Infect. Dis. 179 (Suppl. 1) : S218– S223.
53. Leroy, E. M.,, S. Baize,, V. E. Volchkov,, S. P. Fisher-Hoch,, M. C. Georges-Courbot,, J. Lansoud-Soukate,, M. Capron,, P. Debre,, J. B. McCormick, and, A. J. Georges. 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210– 2215.
54. Leroy, E. M.,, B. Kumulungui,, X. Pourrut,, P. Rouquet,, A. Hassanin,, P. Yaba,, A. Delicat,, J. T. Paweska,, J. P. Gonzalez, and, R. Swanepoel. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438: 575– 576.
55. Leroy, E. M.,, P. Rouquet,, P. Formenty,, S. Souquiere,, A. Kilbourne,, J. M. Froment,, M. Bermejo,, S. Smit,, W. Karesh,, R. Swanepoel,, S. R. Zaki, and, P. E. Rollin. 2004. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303: 387– 390.
56. Leroy, E. M.,, S. Souquiere,, P. Rouquet, and, D. Drevet. 2002. Re-emergence of Ebola haemorrhagic fever in Gabon. Lancet 359: 712.
57. Licata, J. M.,, R. F. Johnson,, Z. Han, and, R. N. Harty. 2004. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78: 7344– 7351.
58. Lucht, A.,, P. Formenty,, H. Feldmann,, M. Gotz,, E. Leroy,, P. Bataboukila,, A. Grolla,, F. Feldmann,, T. Wittmann,, P. Campbell,, C. Atsangandoko,, P. Boumandouki,, E. Finke,, P. Miethe,, S. Becker, and, R. Grunow. 2007. Development of an immunofiltration-based antigen detection assay for rapid diagnosis of Ebola virus infections. J. Infect. Dis. 196 (Suppl. 2) : S184– S192.
59. Mahanty, S.,, and M. Bray. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4: 487– 498.
60. Martini, G. A. 1969. Marburg agent disease in man. Trans. R. Soc. Trop. Med. Hyg. 63: 295– 302.
61. Miranda, M. E.,, T. G. Ksiazek,, T. J. Retuya,, A. S. Khan,, A. Sanchez,, C. F. Fulhorst,, P. E. Rollin,, A. B. Calaor,, D. L. Manalo,, M. C. Roces,, M. M. Dayrit, and, C. J. Peters. 1999. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J. Infect. Dis. 179 (Suppl. 1) : S115– S119.
62. Muhlberger, E.,, M. Weik,, V. E. Volchkov,, H. D. Klenk, and, S. Becker. 1999. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73: 2333– 2342.
63. Mupapa, K.,, M. Massamba,, K. Kibadi,, K. Kuvula,, A. Bwaka,, M. Kipasa,, R. Colebunders, and, J. J. Muyembe-Tamfum for the International Scientific and Technical Committee. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179 (Suppl. 1) : S18– S23.
64. Neumann, G.,, H. Feldmann,, S. Watanabe,, I. Lukashevich, and, Y. Kawaoka. 2002. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 76: 406– 410.
65. Nikiforov, V. V.,, I. Turovskii Iu,, P. P. Kalinin,, L. A. Akinfeeva,, L. R. Katkova,, V. S. Barmin,, E. I. Riabchikova,, N. I. Popkova,, A. M. Shestopalov,, V. P. Nazarov, et al. 1994. A case of a laboratory infection with Marburg fever. Zh. Mikrobiol. Epidemiol. Immunobiol. : 104– 106. (In Russian.)
66. Noda, T.,, H. Ebihara,, Y. Muramoto,, K. Fujii,, A. Takada,, H. Sagara,, J. H. Kim,, H. Kida,, H. Feldmann, and, Y. Kawaoka. 2006. Assembly and budding of Ebola virus. PLoS Pathog. 2: e99.
67. Oswald, W. B.,, T. W. Geisbert,, K. J. Davis,, J. B. Geisbert,, N. J. Sullivan,, P. B. Jahrling,, P. W. Parren, and, D. R. Burton. 2007. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3: e9.
68. Palacios, G.,, T. Briese,, V. Kapoor,, O. Jabado,, Z. Liu,, M. Venter,, J. Zhai,, N. Renwick,, A. Grolla,, T. W. Geisbert,, C. Drosten,, J. Towner,, J. Ju,, J. Paweska,, S. T. Nichol,, R. Swanepoel,, H. Feldmann,, P. B. Jahrling, and, W. I. Lipkin. 2006. MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg. Infect. Dis. 12: 692– 695.
69. Palacios, G.,, P. L. Quan,, O. J. Jabado,, S. Conlan,, D. L. Hirschberg,, Y. Liu,, J. Zhai,, N. Renwick,, J. Hui,, H. Hegyi,, A. Grolla,, J. E. Strong,, J. S. Towner,, T. W. Geisbert,, P. B. Jahrling,, C. Buchen-Osmond,, H. Ellerbrok,, M. P. Sanchez-Seco,, Y. Lussier,, P. Formenty,, M. S. Nichol,, H. Feldmann,, T. Briese, and, W. I. Lipkin. 2007. Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg. Infect. Dis. 13: 73– 81.
70. Panchal, R. G.,, G. Ruthel,, T. A. Kenny,, G. H. Kallstrom,, D. Lane,, S. S. Badie,, L. Li,, S. Bavari, and, M. J. Aman. 2003. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl. Acad. Sci. USA 100: 15936– 15941.
71. Parrino, J.,, R. Hotchkiss, and, M. Bray. 2007. Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg. Infect. Dis. 13: 191– 198.
72. Peterson, A. T.,, D. S. Carroll,, J. N. Mills, and, K. M. Johnson. 2004. Potential mammalian filovirus reservoirs. Emerg. Infect. Dis. 10: 2073– 2081.
73. Pourrut, X.,, A. Delicat,, P. Rollin,, T. Ksiazek,, J. Gonzalez, and, E. Leroy. 2007. Spatial and temporal patterns of Zaire Ebolavirus antibody prevalence in the possible reservoir bat species. J. Infect. Dis. 196 (Suppl. 2) : S176– S183.
74. Reid, S. P.,, L. W. Leung,, A. L. Hartman,, O. Martinez,, M. L. Shaw,, C. Carbonnelle,, V. E. Volchkov,, S. T. Nichol, and, C. F. Basler. 2006. Ebola virus VP24 binds karyopherin α1 and blocks STAT1 nuclear accumulation. J. Virol. 80: 5156– 5167.
75. Richards, G. A.,, S. Murphy,, R. Jobson,, M. Mer,, C. Zinman,, R. Taylor,, R. Swanepoel,, A. Duse,, G. Sharp,, I. C. De La Rey, and, C. Kassianides. 2000. Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit. Care Med. 28: 240– 244.
76. Roddy, P.,, D. Weatherill,, B. Jeffs,, Z. Abaakouk,, P. N. Folo,, M. H. Bengi,, C. Dorion,, P. Rodriguez,, P. P. Palma,, O. de la Rosa,, L. Villa,, I. Grovas, and, M. Borchert. 2007. The Médecins Sans Frontières intervention in the Marburg epidemic Uige/Angola, 2005—II: lessons learnt in the community. J. Infect. Dis. 196 (Suppl. 2) : S162– S167.
77. Rodriguez, L. L.,, A. De Roo,, Y. Guimard,, S. G. Trappier,, A. Sanchez,, D. Bressler,, A. J. Williams,, A. K. Rowe,, J. Bertolli,, A. S. Khan,, T. G. Ksiazek,, C. J. Peters, and, S. T. Nichol. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 (Suppl. 1) : S170– S176.
78. Rollin, P.,, D. Bausch, and, A. Sanchez. 2007. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes of Ebola virus (Sudan) disease in humans. J. Infect. Dis. 196 (Suppl. 2) : S364– S371.
79. Sadek, R. F.,, A. S. Khan,, G. Stevens,, C. J. Peters, and, T. G. Ksiazek. 1999. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J. Infect. Dis. 179 (Suppl. 1) : S24– S27.
80. Sanchez, A.,, T. G. Ksiazek,, P. E. Rollin,, M. E. Miranda,, S. G. Trappier,, A. S. Khan,, C. J. Peters, and, S. T. Nichol. 1999. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J. Infect. Dis. 179 (Suppl. 1) : S164– S169.
81. Sanchez, A.,, M. Lukwiya,, D. Bausch,, S. Mahanty,, A. J. Sanchez,, K. D. Wagoner, and, P. E. Rollin. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 78: 10370– 10377.
82. Sanchez, A.,, K. Wagoner, and, P. Rollin. 2007. Sequence-based HLA-B typing of patients infected with Ebola virus (Uganda 2000): identification of alleles associated with fatal and nonfatal disease. J. Infect. Dis. 196 (Suppl. 2) : S329– S336.
83. Sullivan, N. J.,, T. W. Geisbert,, J. B. Geisbert,, L. Xu,, Z. Y. Yang,, M. Roederer,, R. A. Koup,, P. B. Jahrling, and, G. J. Nabel. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman primates. Nature 424: 681– 684.
84. Sullivan, N. J.,, A. Sanchez,, P. E. Rollin,, Z. Y. Yang, and, G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605– 609.
85. Swanepoel, R.,, P. A. Leman,, F. J. Burt,, N. A. Zachariades,, L. E. Braack,, T. G. Ksiazek,, P. E. Rollin,, S. R. Zaki, and, C. J. Peters. 1996. Experimental inoculation of plants and animals with Ebola virus. Emerg. Infect. Dis. 2: 321– 325.
86. Theriault, S.,, A. Groseth,, H. Artsob, and, H. Feldmann. 2005. The role of reverse genetics systems in determining filovirus pathogenicity. Arch. Virol. Suppl. 2005: 157– 177.
87. Towner, J.,, T. Sealy,, T. Ksiazek, and, S. Nichol. 2007. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J. Infect. Dis. 196 (Suppl. 2) : S205– S212.
88. Towner, J. S.,, X. Pourrut,, C. G. Albariño,, C. N. Nkogue,, B. H. Bird,, G. Grard,, T. G. Ksiazek,, J.-P. Gonzalez,, S. T. Nichol, and, E. M. Leroy. 2007. Marburg virus infection detected in a common African bat. PLoS ONE 2: e764.
89. Towner, J. S.,, P. E. Rollin,, D. G. Bausch,, A. Sanchez,, S. M. Crary,, M. Vincent,, W. F. Lee,, C. F. Spiropoulou,, T. G. Ksiazek,, M. Lukwiya,, F. Kaducu,, R. Downing, and, S. T. Nichol. 2004. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J. Virol. 78: 4330– 4341.
90. Villinger, F.,, P. E. Rollin,, S. S. Brar,, N. F. Chikkala,, J. Winter,, J. B. Sundstrom,, S. R. Zaki,, R. Swanepoel,, A. A. Ansari, and, C. J. Peters. 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179 (Suppl. 1) : S188– S191.
91. Warfield, K. L.,, D. L. Swenson,, G. G. Olinger,, W. V. Kalina,, M. J. Aman, and, S. Bavari. 2007. Ebola virus-like particle vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196 (Suppl. 2) : S430– S437.
92. Warfield, K. L.,, D. L. Swenson,, G. G. Olinger,, D. K. Nichols,, W. D. Pratt,, R. Blouch,, D. A. Stein,, M. J. Aman,, P. L. Iversen, and, S. Bavari. 2006. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2: e1.
93. Wilson, J. A.,, M. Bray,, R. Bakken, and, M. K. Hart. 2001. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286: 384– 390.
94. Wilson, J. A.,, M. Hevey,, R. Bakken,, S. Guest,, M. Bray,, A. L. Schmaljohn, and, M. K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664– 1666.
95. Wool-Lewis, R. J.,, and P. Bates. 1998. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72: 3155– 3160.
96. World Health Organization. 1978. Ebola haemorrhagic fever in Sudan, 1976. Bull. W. H. O. 56: 247– 270.
97. World Health Organization. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. W. H. O. 56: 271– 293.
98. World Health Organization. 2001. Outbreak of Ebola hemorrhagic fever, Uganda, August 2000–January 2001. Wkly. Epidemiol. Rec. 76: 41– 48.
99. Zaki, S. R.,, W. J. Shieh,, P. W. Greer,, C. S. Goldsmith,, T. Ferebee,, J. Katshitshi,, F. K. Tshioko,, M. A. Bwaka,, R. Swanepoel,, P. Calain,, A. S. Khan,, E. Lloyd,, P. E. Rollin,, T. G. Ksiazek, and, C. J. Peters for the Commission de Lutte contre les Epidémies à Kikwit. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. J. Infect. Dis. 179 (Suppl. 1) : S36– S47.

Tables

Filoviruses
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815981.ch41-1,webId=/content/author/10.1128/9781555815981.ch41-1,properties={foaf_givenname=Mike, foaf_name=Mike Bray, foaf_surname=Bray}]]
Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41
/content/10.1128/9781555815981.ch41.ch41tab01
TABLE 1
Known cases and epidemics of filoviral hemorrhagic fever
Generic image for table
TABLE 1

Known cases and epidemics of filoviral hemorrhagic fever

Citation: Bray M. 2009. Filoviruses, p 923-941. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815981.ch41

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error